About 91% of funds recorded in 2020 for all biopharma collaborations with nonprofit entities and 75% of all grant money went directly to therapeutic and vaccine efforts to fight COVID-19. BioWorld has tracked 912 bio/nonprofit deals worth $19.86 billion and 658 grants awarded to the industry and valued at $12.98 billion for a combined total this year of 1,570 and $32.84 billion.

The combined total of biopharma nonprofit collaborations and grants in 2020 has reached about $24 billion, more than three times the amount recorded for 2019.

COVID-19 continues to dominate biopharma nonprofit collaborations and grants in 2020, with the pandemic accounting for 85% of projected values reported this year, most of which have posted since the start of July.

Without a doubt, efforts to fight COVID-19 have dominated the flow of money into the biopharma industry through nonprofit collaborations and grants, accounting for 87% and 85% of the 2020 totals, respectively. Out of the 590 bio/nonprofit deals tracked by BioWorld this year, a total of $7.18 billion has been recorded, but 283 deals valued at $6.24 billion are directly focused on providing therapies for the pandemic.

Swept up into a coronavirus whirlwind, the biopharma industry has ramped up development of therapeutics and vaccines and altered business plans to fight the SARS-CoV-2 virus in a way that nobody could have imagined only months ago.